{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:47:28Z","timestamp":1776833248332,"version":"3.51.2"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.urolonc.2024.11.010","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T12:24:26Z","timestamp":1734179066000},"page":"189.e9-189.e18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world survival and economic burden among patients with locally advanced or metastatic urothelial carcinoma in the United States"],"prefix":"10.1016","volume":"43","author":[{"given":"Ronald C.","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupali","family":"Fuldeore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Greatsinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Hepp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phoebe","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Mucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.11.010_bib0001","unstructured":"National Cancer Institute. SEER cancer stat facts: bladder cancer. 2022. Accessed August 12, 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html"},{"key":"10.1016\/j.urolonc.2024.11.010_bib0002","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1038\/551S34a","article-title":"Unlocking bladder cancer","volume":"551","author":"Berdik","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2024.11.010_bib0003","series-title":"EAU guidelines on muscle-invasive and metastatic bladder cancer","author":"Witjes","year":"2022"},{"key":"10.1016\/j.urolonc.2024.11.010_bib0004","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.2217\/fon-2021-0573","article-title":"Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1\/L1 inhibitor therapy","volume":"17","author":"Hepp","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2024.11.010_bib0005","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2024.11.010_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13827","article-title":"The rapidly evolving landscape of first-line targeted therapy in metastatic urothelial cancer: a systematic review","volume":"26","author":"Lavoie","year":"2021","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.urolonc.2024.11.010_bib0007","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.urolonc.2024.11.010_bib0008","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2024.11.010_bib0009","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.11.010_bib0010","series-title":"PACDEV (enfortumab vedotin-ejfv)","year":"2023"},{"key":"10.1016\/j.urolonc.2024.11.010_bib0011","doi-asserted-by":"crossref","first-page":"76.e15","DOI":"10.1016\/j.urolonc.2020.07.011","article-title":"\"Real-world\" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma","volume":"39","author":"Drakaki","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.11.010_bib0012","series-title":"Table describing changes in codes for NCI Comorbidity Index","year":"2023"},{"key":"10.1016\/j.urolonc.2024.11.010_bib0013","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/13696998.2019.1591424","article-title":"Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma","volume":"22","author":"Aly","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.urolonc.2024.11.010_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.05.001","article-title":"Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1\/L1 inhibitor therapy: a Medicare claims database analysis","volume":"39","author":"Morgans","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.11.010_bib0015","doi-asserted-by":"crossref","first-page":"e909","DOI":"10.1016\/j.clgc.2018.03.002","article-title":"Survival rates and health care costs for patients with advanced bladder cancer treated and untreated with chemotherapy","volume":"16","author":"Flannery","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.11.010_bib0016","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canep.2019.03.013","article-title":"Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting","volume":"60","author":"Simeone","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.urolonc.2024.11.010_bib0017","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/fon-2018-0654","article-title":"Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study","volume":"15","author":"Flannery","year":"2019","journal-title":"Future Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924007440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924007440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T23:39:12Z","timestamp":1744414752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924007440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1078143924007440"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.11.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world survival and economic burden among patients with locally advanced or metastatic urothelial carcinoma in the United States","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}